Linked Life Data

17064073

Source:http://linkedlifedata.com/resource/pubmed/id/17064073

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
22
pubmed:dateCreated
2006-10-26
pubmed:abstractText
The cyclin-dependent kinases (CDKs) and their cyclin partners are key regulators of the cell cycle. Since deregulation of CDKs is found with high frequency in many human cancer cells, pharmacological inhibition of CDKs with small molecules has the potential to provide an effective strategy for the treatment of cancer. The 2,4-diamino-5-ketopyrimidines 6 reported here represent a novel class of potent and ATP-competitive inhibitors that selectively target the cyclin-dependent kinase family. This diaminopyrimidine core with a substituted 4-piperidine moiety on the C2-amino position and 2-methoxybenzoyl at the C5 position has been identified as the critical structure responsible for the CDK inhibitory activity. Further optimization has led to a good number of analogues that show potent inhibitory activities against CDK1, CDK2, and CDK4 but are inactive against a large panel of serine/threonine and tyrosine kinases (K(i) > 10 microM). As one of these representative analogues, compound 39 (R547) has the best CDK inhibitory activities (K(i) = 0.001, 0.003, and 0.001 microM for CDK1, CDK2, and CDK4, respectively) and excellent in vitro cellular potency, inhibiting the growth of various human tumor cell lines including an HCT116 cell line (IC(50) = 0.08 microM). An X-ray crystal structure of 39 bound to CDK2 has been determined in this study, revealing a binding mode that is consistent with our SAR. Compound 39 demonstrates significant in vivo efficacy in the HCT116 human colorectal tumor xenograft model in nude mice with up to 95% tumor growth inhibition. On the basis of its superior overall profile, 39 was chosen for further evaluation and has progressed into Phase I clinical trial for the treatment of cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0022-2623
pubmed:author
pubmed:issnType
Print
pubmed:day
2
pubmed:volume
49
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
6549-60
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:17064073-Animals, pubmed-meshheading:17064073-Antineoplastic Agents, pubmed-meshheading:17064073-Cell Line, Tumor, pubmed-meshheading:17064073-Chemistry, Physical, pubmed-meshheading:17064073-Cyclin-Dependent Kinase 2, pubmed-meshheading:17064073-Cyclin-Dependent Kinases, pubmed-meshheading:17064073-Drug Design, pubmed-meshheading:17064073-Enzyme Inhibitors, pubmed-meshheading:17064073-Female, pubmed-meshheading:17064073-Humans, pubmed-meshheading:17064073-Indicators and Reagents, pubmed-meshheading:17064073-Kinetics, pubmed-meshheading:17064073-Mice, pubmed-meshheading:17064073-Mice, Nude, pubmed-meshheading:17064073-Models, Molecular, pubmed-meshheading:17064073-Physicochemical Phenomena, pubmed-meshheading:17064073-Pyrimidines, pubmed-meshheading:17064073-Structure-Activity Relationship, pubmed-meshheading:17064073-X-Ray Diffraction
pubmed:year
2006
pubmed:articleTitle
Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.
pubmed:affiliation
Department of Discovery Chemistry, Discovery Oncology, Non-Clinical Drug Safety and Discovery Technologies, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, NJ 07110, USA. xin-jie.chu@roche.com
pubmed:publicationType
Journal Article